PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH HIV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 确定BMS-232632胶囊制剂联合两种NRTI在HIV感染儿童和青少年中的药代动力学特征和给药方案。 确定BMS-232632粉末制剂联合NRTI在HIV感染婴儿和儿童中的药代动力学特征和给药方案。 确定BMS-232632在HIV感染婴儿、儿童和青少年中的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the pharmacokinetic profile and dosing schedule for the capsule formulation of BMS-232632 in combination with two NRTIs in HIV infected children and adolescents. To determine the pharmacokinetic profile and dosing schedule fo rhte powder formulations of BMS-232632 in combination with NRTIs in HIV infected infancts and children. To determine the safety and tolerability of BMS-232632 in HIV infected infants, children and adolescents.